Dr. Linda L. Garland
Director, Clinical Lung Cancer Program
University of Texas Health Science Center - 1988
University of South Florida College of Medicine
H. Lee Moffitt Cancer Center
As a medical oncologist, Dr. Linda Lee Garland coordinates and oversees medical care for patients with cancer. She specializes in experimental therapeutics in the treatment of chest cancers, including lung cancer and mesothelioma. Dr. Garland is the director of the Clinical Lung Cancer Program at the University of Arizona Cancer Center located in Tucson, Arizona and is a full investigator in the Cancer Prevention and Control Program. She also teaches at the University of Arizona College of Medicine, where she is an associate professor of clinical medicine.
Dr. Garland attended medical school at the University of Texas Health Science Center in San Antonio, Texas, then went on to complete a residency in internal medicine at the University of South Florida College of Medicine. She specialized in hematology and oncology during a fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida.
Clinical and Laboratory Research
Dr. Garland has built her career around searching for promising new ways to fight for cancer. Experimental therapeutics is the main focus of her research, particularly related to malignant diseases of the chest. Chemotherapy has limited effectiveness when dealing with lung cancers, especially because the disease tends to be diagnosed at a late stage. Therefore, doctors like Dr. Garland are interested in exploring other treatments, including new chemotherapy drugs that may be more effective at fighting tumors while causing fewer side effects.
Dr. Garland is board certified by the American Board of Internal Medicine in the area of Medical Oncology.
Garland L., Flores F., Tsao A. “Individualizing mesothelioma treatment: Small Steps into a Brighter Future”, Clinical Lung Cancer, Vol. 11, No. 6, 371-373.
Garland L, Rankin C, Gandara D, Rivkin S, Scott K, Nagle R, Altomare D, Klein-Szanto A, Testa R, Borden E. “A Phase II study of oral EGFR tyrosine kinase inhibitor erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study.” J Clin Oncol 2007:25; 2406-2413.
Garland L, Taylor C, Pilkington D, Cohen J, Von Hoff D. “A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative With Polo-Like Kinase-1 Interacting Properties, in Patients With Advanced Solid Tumors.” Clin Cancer Res 2006:12; 5182-9.Sources
Linda Garland, M.D.
“Surgeons Extending Lives in Battle Against Mesothelioma”
“Individualizing Mesothelioma Treatment: Small Steps Into a Brighter Future”